INTrOduCTION
Most patients with cystic fibrosis (CF) have a suboptimal nutritional status. In order to minimize morbidity and mortality, obtaining and maintaining a good nutritional status remains one of the important challenges in CF. [1] [2] [3] Next to preventing and controlling pulmonary infections, a high dietary energy intake diet combined with pancreatic enzyme replacement therapy (PERT) are classic cornerstones in CF care.
Despite optimizing and maximizing PERT, fat malabsorption in most CF patients persist (CFPFM) . Rather than the physiological absorption above 95%, most CF patients show a decreased intestinal fat absorption of ± 85-90% of dietary fat intake. 4, 5 It is reasonable to assume that at least part of the failure to approach a physiological degree of fat absorption could still be attributed to inefficiency and inaccurate dosing of PERT. Also, a non-synchronous entrance of PERT with dietary energy intake into the duodenum may play a role in CFPFM. 6 However, besides PERT related issues, other factors have been implied to be involved in CFPFM. 7, 8 During the last decades, several of these potential contributing factors to CFPFM have been addressed and investigated in patient studies as well as animal studies. In this review, we will provide an overview of the different mechanisms that have been implied to contribute to CFPFM and describe the results of corresponding interventional studies on fat absorption and/or nutritional status. We will mainly describe studies performed in CF patients and CF mice. CF mice are especially suitable to exclusively investigate CFPFM, as most CF mouse models do not suffer from pancreatic insufficiency but do exhibit impaired absorption of fat. 9 Based on the reviewed literature, we will conclude our review with clinical implications and suggestions for further research.
In order to fully recognize and understand the CF-related factors that might be involved in CFPFM, we start to describe the physiological process of fat digestion and absorption.
phYSIOLOGY OF FaT dIGESTION aNd aBSOrpTION
Dietary fat intake mainly consists of long-, medium-and short-chain triglycerides. The mechanism of digestion and absorption of these lipids can be dissected into several sequential steps. In contrast to long-chain triglycerides, medium-and short-chain triglycerides are known to circumvent several steps in lipid digestion and absorption. For example, unlike long-chain triglycerides, medium-and short chain triglycerides are less dependent upon solubilization, escape the re-esterification into triglycerides and are directly absorbed into the portal system without being assembled into chylomicrons. 10 Since the majority of dietary fat and energy intake consists of longchain triglycerides (92-96%), we exclusively focused on their mechanism of intestinal digestion and absorption. The mechanism of digestion and absorption of long-chain triglycerides can be dissected into several sequential processes (figure 1A).
1) Emulsification.
Emulsification of triglycerides is a process in which (water-insoluble) fat droplets are suspended in an aqueous environment. Emulsification can be achieved by mechanical as well as chemical means. Mechanical emulsification is attained by chewing and forcing dietary fat with high pressure through a small opening (e.g. the pylorus) and dispersing large fat droplets into smaller droplets. Chemical emulsification is attained by the action of bile and prevents the emulsion from re-coalescing. Emulsification results in a fine, relatively stable oil-in-water emulsion with an increased surface area. The water soluble digestive / lipolytic enzymes are active at the site of the water-oil interface.
2) Lipolysis. During lipolysis, the breakdown (hydrolysis) of lipids into smaller particles is continued. Around 10-30% of the triglycerides are hydrolyzed in the stomach into diglycerides and free fatty acids, catalyzed by lingual and gastric lipase (a process also known as biochemical/lipolytic emulsification 10 ). Under physiological conditions, pancreatic lipase completes the process in the proximal part of the small intestine, by hydrolyzing the remaining triglycerides and diglycerides into monoglycerides and free fatty acid molecules. Bile salts are amphipathic molecules, i.e. they possess a hydrophilic and a hydrophobic site. Upon exposure to dietary lipid emulsion at the level of the proximal small intestine, the hydrophobic site orients itself towards the hydrophobic lipid droplets, whereas their hydrophilic site exposes itself to the aqueous (water) phase. Lipids droplets whose surface is thus covered bile salts are not accessible to pancreatic lipase. Pancreatic co-lipase allows the anchoring of the pancreas lipase to the oil-water interface and is essential for lipolytic activity. Under physiological conditions, pancreatic lipase is present in vast excess. Thus, in CF, fat maldigestion only occurs during severe pancreatic malfunction. 11 During exocrine pancreatic insufficiency when pancreatic lipase is severely reduced, lipolysis is more dependent upon the activity of lingual and gastric lipase. In CF conditions, lingual lipase remains fully active in the intestine, where it accounts for more than 90% of lipase activity, even when the intestinal pH drop below the optimal level for bile salt dependent lipolysis. 80 3) Solubilization. The process in which fat molecules are dissolved in water in the form of (mixed) micelles is called solubilization. Solubilization enhances the aqueous solubility of fatty acids by several orders of magnitude (100 to 1000 fold). 10 Solubilization is necessary for monoglycerides and free fatty acids to efficiently overcome the diffusion barrier of the so called unstirred water layer of the enterocytes. 10 The unstirred water layer separates the enterocytes from the luminal contents of the intestine. Solubilization is achieved by the formation of mixed micelles; mainly consisting of phospholipids and bile salts derived from biliary secretion. The diameter of the lipid droplets ranges from 100 -1000 nm, whereas that of mixed micelles ranges 3-5 nm. The hydrophobic part of the lipid molecules, such as the acyl-chains, will be oriented inwards, whereas the hydrophilic parts, (such as the carboxylic headgroups) orients towards the aqueous outside of the micelle. Saturated fatty acids are more dependent on solubilization than unsaturated fatty acids, due to the higher hydrophobicity of the former. The difference in bile salt dependency can be derived from absorption studies in rats with chronic bile diversion: in such an intestinal bile deficient condition, absorption of saturated fatty acids is below 30% of the ingested amount, while the absorption of unsaturated fatty acids is relatively maintained (~80%). 13 Just like the digestion of fat, the process of micelle formation is also pH sensitive. Low intestinal pH levels can severely inhibit micelle formation or induce premature release of lipolytic products out of micelles. 10
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4) Translocation.
Once the mixed micelles diffuse through the unstirred water layer and arrive at the proximity of the (apical) enterocyte membrane, the free fatty acids and monoglycerides dissociate from the micelles. It has been postulated that the acidic microclimate near the apical membrane of intestinal mucosal cells, induces micelle-disintegration and favours the translocation of fatty acid molecules across the enterocyte membrane. 10 It has remained unclear whether intestinal membrane transporters are essential for the translocation of fatty acids and monoglycerides. It is suggested that free fatty acid uptake is concentration-dependent, in which a high intraluminal concentration drives passive diffusion. Two putative intestinal transporters have been proposed to be involved fatty acid uptake; the fatty acid binding protein (FABP) and the fatty acid translocase / cluster determinant 36 (FAT/CD36). 14 However, both transporters are not likely to be involved in fatty acid uptake into the enterocytes. FABP is only expressed in a small area of the crypt-villus of the intestine and knockout mice for FABP and CD36 do not exhibit impairments in fatty acid uptake. [15] [16] [17] 5) Intracellular processing. After being absorbed into the enterocytes, the lipolytic products migrate to the endoplasmic reticulum, possibly mediated via the fatty acid binding proteins. [14] [15] At the cytoplasmic surface of the endoplasmic reticulum, the fatty acids and monoglycerides are re-esterified into triglycerides. Under physiological conditions, re-esterification mainly occurs via the monoacylglycerol pathway, i.e. the sequential acylation of monoacylglycerol by acyl-CoA. 10 6) Chylomicron production. Newly synthesized triglycerides are transferred into the smooth endoplasmic reticulum and are assembled into lipoprotein particles called chylomicrons. Intestinal phospholipids are required for chylomicron production in order to prevent accumulation in the enterocyte. [18] [19] Maturation of chylomicrons (i.e. assembly of fat particles with a phospholipid-cholesterol-apolipoprotein surface) takes place in the Golgi apparatus. Chylomicron formation is followed by exocytosis via the secretory pathway at the basolateral surface of the enterocyte. The chylomicrons are released into the circulation via the mesenteric lymph system, via the thoracic duct into the venous system, after which their contents are systemically delivered.
FaCTOrS prOpOSEd TO BE aSSOCIaTEd WITh pErSISTENT FaT MaLaBSOrpTION IN CF
Several factors have been proposed to contribute to CFPFM. For each of these factors we will describe; 1 how these factors are affected in CF conditions; 2 what is known about the relation of these factors with CFPFM; and, 3 what the result of intervention studies are in CF patients and CF mice when improving or altering these factors.
3.1
Intestinal pH 1) CF conditions. CFTR dysfunction reduces pancreatic and duodenal bicarbonate secretion. [20] [21] Gastric bicarbonate secretion in CF patients is not affected. 22 Hence, the duodenal pH is (on average) 1-2 units lower in CF patients compared with healthy controls. Also, CF patients have significantly longer periods (postprandial) in which the duodenal pH drops below 4. 23 The pH values in jejunal and ileal contents from CF patients vary from lower to similar pH values compared with healthy controls. 23 CFTR tm1Cam knockout mice have adequate pancreatic bicarbonate secretion, but probably do have reduced secretions of duodenal bicarbonate. 9 This might explain the observation in CFTRtm1Unc knockout mice , where duodenal pH is only minimally reduced (~0.25). 21 2) Relation with CFPFM. A normal intestinal pH is essential for adequate digestion and absorption of fat. 10 Recently, Quinton et al. showed that adequate bicarbonate secretion is essential for mucin expansion in the intestine. [24] [25] When mucin expansion is disturbed by inadequate release of bicarbonate in CF conditions, viscous and sticky mucus might impair translocation of lipids to the enterocyte. A strong relation has been described between postprandial duodenal pH levels and the degree of fat malabsorption in CF patients treated with pancreatic enzymes. 26 These data indicate that interventions to increase intestinal pH values might improve CFPFM.
3) Intervention studies. Two double-blind crossover studies evaluated fat absorption in pediatric and adult CF patients after the addition of bicarbonate to enteric coated pancreatic enzymes. In the first study, the average fat absorption increased from 75% to 82% of the ingested amount. 27 In this study, a beneficial effect on fat absorption was observed in seventy-five percent of the patients. In the second study, the average fat absorption did not increase, but fifty percent of patients did show an improvement in fat absorption (>5%) after bicarbonate supplementation. 28 Due to the overall minimal observed changes in fat absorption, pancreatic enzymes buffered with bicarbonate are not implemented in CF care.
In a systematic review, Jones A. evaluated the effect of acid suppressant therapy on fat absorption and/or faecal fat excretion and nutritional status. 29 While multiple studies reported improved fat absorption or reduced faecal fat excretion after acid suppressive therapy, other studies reported no improvements. Improved fat absorption was not accompanied with an improvement in nutritional status. The performed studies showed high variability in the used dosage of pancreatic enzymes, choice of acidic suppressive medication and differed in the inclusion criteria for the degree of fat malabsorption. Due to these large inter-study differences, it remains difficult to draw an overall definite conclusion about the effectiveness of acid suppressive drugs. Evaluating individual data in these intervention studies, a subgroup of patients clearly showed improved fat absorption. The results indicate that some CF patients do benefit from acid suppressive therapy. Why some patients respond, but others show no improvement in fat absorption, illustrates that an altered pH is not the only factor responsible CFPFM. Next to this, it is known that acid suppressive drugs can induce small intestinal bacterial overgrowth (SIBO) and can alter bile salt metabolism, with a potentially negative effect on fat absorption. 30 Therefore, acid suppressive therapy should be imposed with caution, especially in CF patients who are relatively more prone to SIBO. A trial of proton pump inhibitors might be useful to evaluate its effectiveness in the individual CF patient.
Bijvelds et al. investigated the effect of the acidic suppressive drug omeprazole on lipolysis and uptake of lipolytic products in CFTR tm1CAM knockout mice by using radioisotope labelled triglycerides and fatty acids. The researchers showed that lipolytic activity and lipid absorption improved after omeprazole treatment.9 It is likely that increasing the intestinal pH has a general positive effect on intestinal fat absorption, since lipolytic and post-lipolytic activity also partially improved in the omeprazole treated wild type mice. 9 3.2 Intra-luminal bile salts 1) CF conditions. CF patients have an increased loss of faecal bile salts. 31, 32 It is speculated that the loss of bile salts is due to impaired bile salt uptake by intestinal mucosal alterations; like thickening of the mucus barrier and/or SIBO. 33 Because the biosynthesis of taurine is limited in humans, the faecal loss of bile salts induces an increased glycine/ taurine ratio of conjugated bile salts in CF patients. 34 In addition, CF patients have an altered bile salt composition in gallbladder bile. Due to a quantitative increase in biliary cholate, the percent contribution of cholate is higher, and the percent contribution of chenodeoxycholate and deoxycholate is lower in the bile of CF patients. 35 2) Relation with CFPFM. It has been proposed that excessive faecal loss of bile salts diminishes the bile salt pool in CF patients and consequently impairs fat absorption by reducing the solubilization capacity of bile. 31 However, a subsequent study indicated that the amount of faecal bile salt excretion was not related to the degree of fat malabsorption in CF patients. 32 Strandvik et al. showed that adult CF patients have normal to large bile salt pool sizes and similar amounts of duodenal bile salts as healthy controls. 35 Bile salt synthesis was normal or even increased, indicating that CF patients adequately compensate for the faecal bile salt loss. We confirmed in CF mouse models that faecal loss of bile salts does not influence the absorption of fat. 9 Homozygous ∆F508 mice and CFTR tm1CAM knockout mice both exhibit, to the same extent, an increased faecal loss of bile salts, but only the CFTR tm1CAM knockout mice had fat malabsorption. 9 In conclusion, bile salt malabsorption in itself, at the levels observed in CF patients and CF mice, does not seem to contribute to CFPFM.
Theoretically, the increased glycine/taurine ratio may impair fat absorption in an acidic intestinal lumen. Due to the higher pKa of glycine, glycine conjugated bile salts are less able to remain in micellar solution. 36 In addition, part of the glycoconjuates are passively absorbed in the in the proximal part of the intestine and are, in comparison to tauroconjugates, less resistant to bacterial degradation. [37] [38] Deoxycholate and chenodeoxycholate are relatively hydrophobic in comparison to other bile salts. Therefore, a reduction in these bile salts may theoretically impair fat absorption by diminishing the solubilization capacity of bile. In general, the percent contribution, and not the quantitative amount, of deoxycholate and of chenodeoxycholate is diminished in CF patients. Thus, the altered bile salt composition is not likely to contribute to CFPFM. This hypothesis is supported by the fact that both homozygous ∆F508 mice and CFTR tm1CAM knockout mice show these alterations, while only the CFTR tm1CAM knockout mice exhibit fat malabsorption. 9 3) Intervention studies. Multiple studies showed that taurine supplementation reduces faecal fat excretion and improves the nutritional status of CF patients, particularly in patients with severe steatorrhoea. [39] [40] [41] However, the beneficial effect of taurine supplementation on fat absorption is not unequivocally demonstrated. [42] [43] [44] [45] Furthermore, the degree of fat absorption did not relate to changes in the serum glycine/taurine ratio in CF children. 45 Altogether, the use of taurine supplementation remains controversial and is not implemented in nutritional CF care.
3.3
Intestinal mucosal abnormalities 1) CF conditions. Several intestinal mucosal abnormalities are described in CF patients. These abnormalities include accumulation of viscous and sticky mucus, SIBO, ileal hyperthrophy and villous atrophy, increased intestinal permeability and (chronic) inflammation of the small intestine. [46] [47] [48] [49] [50] [51] [52] [53] 2) Relation with CFPFM. All the above mentioned factors may theoretically contribute to fat malabsorption in CF patients, as they might impair adequate translocation of fatty acids in(to) the enterocyte. In addition, SIBO might impair micelle formation by the bacterial deconjugation of bile salts. 54 However, no studies evaluated the actual contribution of intestinal mucosal abnormalities to CFPFM.
3) Intervention studies. The group of De Lisle et al. evaluated the effect of antibiotic treatment on intestinal inflammation, mucus accumulation and SIBO in CFTRtm1Unc knockout mice. 55 CFTRtm1Unc knockout mice display a phenotype of SIBO with a 400 fold increase in small intestinal bacterial content compared to wild type littermates.56 Broad spectrum antibiotic treatment with ciprofloxacine and metronidazole did not only reduce the bacterial load in the small intestine, but also decreased intestinal mucus accumulation and inflammation. More importantly, three weeks of treatment substantially improved the body weight of these mice. The same effect on the bacterial load, intestinal mucus accumulation, inflammation and body weight was observed after laxative treatment. 57 It remains to be elucidated whether the growth benefit was due to improved fat absorption, reduced competition for nutrients by intestinal bacteria or due to reduced intestinal inflammation. As O'Brien et al. showed that a seven-day treatment with metronidazole reduced faecal fat excretion in four CF patients 32 , it is reasonable to assume that the increased weight is due to improved fat absorption Although the effect on fat absorption was not assessed in either of these studies, the results suggest that metronidazole might be a potential therapeutic option for increasing fat absorption or nutritional status in CF patients.
One study evaluated the effect of probiotics on intestinal inflammation in CF patients. 49 It has been suggested that probiotics improve intestinal barrier function and modify the immune response. 58 Bruzzese et al. reported that a four week treatment with Lactobacillus rhamnosus GG, reduced faecal calprotectin levels (marker for intestinal inflammation) in 8 out of 10 treated CF patients. 49 The long term effect of probiotics on intestinal inflammation was not evaluated, nor the effect on fat absorption or nutritional status. We found only one mice study which evaluated fat absorption after probiotics; lactobacillus supplementation increased intestinal absorption of dietary lipids in germfree mice colonized with human baby flora. 59 Until now, the clinical value of probiotics and its relation with fat absorption in CF patients is not clear.
Small intestinal transit time
1) CF conditions. No studies exclusively investigated small intestinal transit in CF patients, but several groups have evaluated the oro-cecal transit time (OCTT). 23 The lactulose/hydrogen breath test was most commonly applied to for determination of the OCTT. Eighty five percent of CF patients had a prolonged OCTT (at least +50%) in the fasted state. [60] [61] Another method to evaluate intestinal activity is by measuring the intestinal muscle activity during the inter-digestive state, also known as the migrating motor complex. The migrating motor complex indirectly reflects the ability to transit food through the intestine. Hallberg et al. showed that duodenal motility during fasting was normal in 8 out of 10 CF patients. 22 This contradiction with transit studies underlines the necessity to evaluate small intestinal transit in CF patients. Especially, since intestinal smooth muscle activity shows an erratic pattern and is unresponsive to cholinergic stimulation in CFTRtm1Unc knockout mice. 62 It has been repeatedly shown, that these mice have a slower small intestinal transit time in comparison to wild type littermates on the same diet. 57, 64 2) Relation with CFPFM. Fat absorption partly depends on the time fat is in contact with the absorptive epithelium of the intestine. A classical thought is that during fat malabsorption the intestine prolongs the intestinal transit time (as a compensatory mechanism), in order to enhance its ability to absorb fat; a phenomenon also known as the 'ileal brake'. 63 It is reasonable to assume that this compensatory mechanism also occurs in CFPFM as intestinal transit time is prolonged in CF. However, prolonged intestinal transit time is also a risk factor for the occurrence of SIBO in CF conditions. 8 Therefore, one might ask, if prolonged intestinal transit time might actually induce or worsen CFPFM. The relation between intestinal transit time and CFPFM is not yet evaluated.
3) Intervention studies. The research group of De Lisle et al. performed several (intervention) studies on gastro-intestinal transit in CFTRtm1Unc knockout mice. 57, 62, 64 Oral laxative treatment improved circular smooth muscle function in the small intestine and normalized intestinal transit time. 62 Moreover, as earlier described, laxative treatment reduced intestinal mucus accumulation, eradicated overgrowth of bacteria in the small intestine and improved body weight. 57 Unfortunately, fat absorption was not evaluated in these studies. It is tempting to speculate that laxative treatment may also improve the nutritional status in CF patients, but before recommendations could be made, more clinical data are needed.
3.5
Essential fatty acid deficiency 1) CF conditions. Despite high fat diets and PERT, CF patients can still have a deficiency in essential fatty acids (EFA). 14 In general, many CF patients have subnormal levels of serum and tissue linoleic acid (LA) and cervonic acid (DHA), often with increased levels of arachidonic acid (AA). 14, [65] [66] The reduction in EFA levels is, apart from fat malabsorption, due to many other CF-related factors. The exact mechanism behind the alterations in EFA's still requires further exploration, but increased lipid turnover in cellular membranes and increased oxidation of EFA's are considered to play the most prominent role. 14, [67] [68] [69] [70] 2) Relation with CFPFM. In relation to fat malabsorption, the EFA content in the intestine is very important. EFA's provide fluidity and flexibility to a cell membrane and play an important role in the maintenance of cell membrane functionality of the enterocyte. EFA deficiency in itself can cause fat malabsorption by affecting the absorption capacity of the intestine. 74 Apart from reduced LA and DHA levels, increased levels of AA in the CF intestine could also (indirectly) affect fat absorption, by contributing to intestinal inflammation, mucus secretion and intestinal smooth muscle relaxation. 79 It has been shown that EFA deficiency affects both the intra-luminal and intra-cellular process of fat absorption, as exemplified in (non-CF) animal models. 69 While the degree of EFA deficiency in CF patients is generally mild, we cannot exclude the possibility that it might interact with fat absorption. Especially since serum EFA levels do not necessarily correlate with EFA levels in the intestine. [75] [76] Ex vivo experiments on intestinal biopsies from CF patients indicated that abnormal intracellular lipid processing occurs in the enterocyte. 75 A low incorporation of 14 C palmitic acid in triglycerides was found in cultures of duodenal biopsies after 18 hours of incubation. The secretion of triglyceriderich chylomicrons was reduced in comparison to intestinal biopsies from healthy controls.75 Whether this impaired lipid transport is due to EFA deficiency, to aberrant CFTR itself or to a complex relation between the two, requires further investigation. 77, 78 To what extent reduced intestinal EFA levels in CF patients interfere with the actual percent absorption of dietary fat intake is unknown. An association has been described between the degree of EFA deficiency and the nutritional status of CF patients 80 , but EFA deficiency can also be present in well nourished CF patients. 81 Thus, the clinical relevance of the reduced EFA levels in CF patients on fat malabsorption remains to be determined.
3) Intervention studies. Despite the abundance of (intervention) studies 66, [82] [83] [84] [85] , no study determined the effect of EFA supplementation on CFPFM. Improved DHA levels in duodenal mucosa of CF patients after 70 mg of DHA/kg body weight for six weeks has been reported 66 , but whether this improved fat absorption or nutritional status was not described. Reviews on omega 3 fatty acid supplementation or DHA supplementation alone, conclude that there is still insufficient evidence for the therapeutic effect of omega 3 fatty acids to recommend the routine use in CF patients. 82, 85 Other studies showed that energy supplements rich in LA improved the body weight in CF patients, but it is hard to differentiate between the effects of LA from that of a high energy intake. [83] [84] Accordingly, we do not recommend the routine use of EFA supplements in CF for reasons to enhance fat absorption, but it could be considered to improve nutritional status in individual cases.
SuMMarY, CLINICaL IMpLICaTIONS aNd FuTurE pErSpECTIVES
Several factors have been proposed to contribute to CFPFM (table 1) . Based on the available data we consider it not likely that bile salt alterations do contribute to CFPFM. The quantitative contribution of intestinal mucosal abnormalities, small intestinal transit time and EFA deficiency to CFPFM remains to be determined. Based on the findings in CF mouse models, CF patients with signs of small bacterial overgrowth might benefit from treatment with broad-spectrum antibiotics. Antibiotic treatment should preferably be evaluated with changes in nutritional status or fat absorption, using three day fat balances. However, we should realize that three day fat balances show high intra-individual variability, which exemplifies the need for novel methodologies to assess fat absorption in CF patients. So far, the influence of reduced duodenal pH levels seems most convincingly demonstrated to play a role in CFPFM. Although not necessarily beneficial in all CF patients, a trial of acid suppressive drugs might be helpful to optimize fat absorption in individual cases.
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